Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in anti-Gal response during chronic rejection.

The recent advances in avoiding hyperacute rejection by producing transgenic pigs with complement regulatory proteins call for the analysis of posttransplantation changes in anti-Gal activity in the absence of hyperacute rejection. Transplantation of cynomolgus monkeys with porcine or bovine meniscus and articular cartilage enabled the study of anti-Gal IgG response to xenografts that are not subjected to hyperacute rejection. The cartilage implants were kept in suprapatellar pouches of the recipients for 1 or 2 months and anti-Gal activity was measured in the serum at various time intervals after transplantation. Within 2 weeks after transplantation, titer of anti-Gal IgG, in all transplanted monkeys, increased by 20- to 100-fold, as measured in ELISA with synthetic alpha-galactosyl epitopes linked to bovine serum albumin or with mouse laminin. Furthermore, binding of serum anti-Gal to porcine endothelial cells increased by 10-fold or more after transplantation. Complement-mediated cytotoxicity also increased by two- to eightfold after transplantation. The elevated activity of anti-Gal was maintained for the 2-month period during which the grafts were kept in the monkeys, and returned to the pretransplantation level 6 months after graft removal. All these data suggest that the primate immune system responds vigorously to alpha-galactosyl epitopes on xenografts by activating many B lymphocytes that produce increased amounts of anti-Gal IgG, which may also be of high affinity. These antibodies are likely to bind to the xenograft cells, even if these cells express low numbers of alpha-galactosyl epitopes. Such antibody binding may play an important role in chronic rejection of xenografts.

[1]  D. Cooper,et al.  Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. , 1992, Transplantation proceedings.

[2]  J. Griffiss,et al.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora , 1988, Infection and immunity.

[3]  R. Morris,et al.  Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. , 1995, Transplantation.

[4]  J. Platt,et al.  Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury , 1995, Nature Medicine.

[5]  C. Groth,et al.  Anti‐Gal activity In diabetic patients transplanted with fetal porcine Islet cell clusters , 1995, Transplantation.

[6]  U. Galili,et al.  Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells. , 1993, Journal of immunology.

[7]  J. Platt,et al.  Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. , 1995, Journal of immunology.

[8]  T. C. Hsieh,et al.  Structures of the asparagine-linked sugar chains of laminin. , 1986, Biochimica et biophysica acta.

[9]  E. Setter,et al.  A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody , 1995, The Journal of experimental medicine.

[10]  J. Okabe,et al.  トランスジェニックマウスおよびトランスジェニックブタにおけるα(1,2)フコシルトランスフェラーゼの発現によるGal(α1,3)Galのレベルの低下 , 1996 .

[11]  A. Gabrielli,et al.  Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (αl‐3)‐galactose epitopes , 1991, Clinical and experimental immunology.

[12]  E. Setter,et al.  Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis , 1995, Nature Medicine.

[13]  U. Galili Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. , 1993, Immunology today.

[14]  M. Radic,et al.  One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. , 1993, Blood.

[15]  D. White,et al.  The generation of transgenic pigs as potential organ donors for humans , 1995, Nature Medicine.

[16]  U. Galili,et al.  Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. , 1997, Transplantation.